Sernova (TSE:SVA) Shares Down 2.2% - Should You Sell?

Sernova Corp. (TSE:SVA - Get Free Report)'s share price fell 2.2% on Thursday . The company traded as low as C$0.23 and last traded at C$0.23. 135,401 shares were traded during trading, a decline of 18% from the average session volume of 164,533 shares. The stock had previously closed at C$0.23.

Wall Street Analyst Weigh In

SVA has been the subject of several research analyst reports. Ventum Financial cut their price target on Sernova from C$3.00 to C$2.50 and set a "buy" rating for the company in a report on Friday, September 13th. Ventum Cap Mkts raised shares of Sernova to a "strong-buy" rating in a research note on Thursday, September 12th. Finally, Leede Financial dropped their price objective on shares of Sernova from C$3.00 to C$1.50 and set a "speculative buy" rating for the company in a research note on Friday, September 13th.

Sernova Stock Performance

The company has a 50-day moving average price of C$0.25 and a two-hundred day moving average price of C$0.28. The stock has a market cap of C$74.82 million, a P/E ratio of -1.73 and a beta of 1.35. The company has a current ratio of 0.32, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55.

Sernova (TSE:SVA - Get Free Report) last posted its quarterly earnings data on Monday, September 16th. The company reported C($0.02) earnings per share for the quarter, beating analysts' consensus estimates of C($0.03) by C$0.01. On average, research analysts expect that Sernova Corp. will post -0.08 EPS for the current fiscal year.

About Sernova

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.